A Phase 1 interventional study of Transplant uses frozen anonymous stool and Transplant uses fresh familial stool in Clostridium Difficile, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2019-03-06.
Sponsored by Mayo Clinic · Phase 1, Interventional, and Treatment
The primary goal of this study will be to assess whether stool collected and frozen from anonymous screened unrelated donors can be as effective as stool freshly collected from recipient's parents when used in Fecal Microbial Transplant for the eradication of recurrent Clostridium difficile infections in children. In the current protocols, which are more than 90% effective, each child who is receiving a fecal transplant has to provide their own donor stool, usually from a parent or close relative. This requires considerable screening costs for each case and is logistically complicated as the donor must be present and must stool just prior to the transplant. The investigators hope to show that a small number of healthy donors can provide stool samples which can be frozen and banked and then thawed for use in numerous patients. The primary goal is to show that Clostridium difficile will be eradicated as effectively (Greater than 90% success) when using the stool from the frozen donors.
The study will also evaluate the inflammatory response and intestinal microbiome in young children aged 1-3 years with Clostridium difficile infections to better predict which ones will respond to fecal transplantation and which ones have incidental infections. For this question the investigators will gather stool samples to check for lactoferrin, calprotectin, and alpha1antitrypsin, and 16s ribosomal RNA analysis in children before and after the fecal transplants. The goal is to see if there is an intestinal microbiome that predisposes some children to getting sick from Clostridium difficile versus just having it incidentally.
The study is designed to enroll forty children aged 1-18 with recurrent Clostridium difficile Infection (CDI). Recurrent CDI is defined as an infection that persists after three rounds of appropriate antibiotics. Enrollees will be randomly assigned to receive Fecal Microbial Transplant using stool from either a screened relative as per current protocols versus using frozen stool that has been collected from healthy volunteers.
Primary outcome will be the eradication of the Clostridium difficile as defined by elimination of diarrhea with a negative Clostridium difficile toxin stool test.
Secondary outcomes will include a measure of quality of life pre and post Fecal Microbial Transplant using a validated quality of life survey instrument, the Health Act Child Health Questionnaire. The investigators will also assess for inflammation in the stool using lactoferrin and calprotectin and evaluate the stool microbiome in recipients pre and post transplant using sequencing to look for any pattern that predicts successful eradication.
310 studies on the registry are indexed under Clostridium Infections; 50 are open to participants now.
This study's enrollment of 28 is below the median of 65 across 233 interventional studies indexed under Clostridium Infections.
Browse Clostridium Infections studies →Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.
Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Eligible children between aged 1 and 18 years must have had Clostridium difficile infection that has not been eradicated despite at least two courses of antibiotics ( either metronidazole or vancomycin).
Inclusion criteria:
Exclusion Criteria:
Undergoes Fecal Microbial Transplant using fresh stool from a screened family member Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
Biological: Transplant uses fresh familial stool
Undergoes Fecal Microbial Transplant using stool collected from screened anonymous donor that has been frozen until time of Fecal Microbial Transplant Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
Biological: Transplant uses frozen anonymous stool
The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.
Also known as: fecal microbial transplant
The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
Also known as: fecal microbila transplant
Clostridium difficile (CD) Eradication; percentage of patients with negative CD toxin in stool following Fecal Microbiota Transplant
Will analyze stool sample collected 4 weeks after fecal microbiota transplant (FMT) for presence or absence of Clostridium difficile toxin. In addition, will note whether presenting symptoms improved or not after FMT.
Time frame: 4 weeks
Changes in quality of life questionnaire scores after Fecal Microbiota Transplant
Will assess quality of life using standardized Child health Questionnaire which provides a raw score of 0-100. Investigators will compare scores of all patients before Fecal Transplant and 12 weeks after in order to mark the impact of procedure outcome on children's physical and psychological health
Time frame: 12 weeks
percentage of patients with stool Calprotectin levels exceeding 50 mcg/g after Fecal Microbiota Transplant
Will assess fecal Calprotectin levels in stools prior to fecal transplant and 4 weeks after
Time frame: 4 weeks
percentage of patients with positive Lactoferrin inflammatory marker in stools after Fecal Microbiota Transplant
Analyze stool samples for presence or absence Lactoferrin before Fecal transplant and 4 weeks after
Time frame: 4 weeks
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mayo Clinic